Limitations of de novo peptide sequencing in resolving sequence ambiguity
A benchmark of eight deep learning tools that sequence peptides directly from mass spectra (de novo) shows that their errors mostly stem from incomplete spectra, not model design, calling for tools that flag uncertain regions instead of guessing full sequences.